Ind-Swift Laboratories profit and loss

Latest FY26

Revenue: ₹641cr+14.2% on FY25
EBITDA: ₹45.1cr−₹19.4 cr in FY25
Net profit: ₹41.4cr−83.5% on FY25
EPS: ₹4.95−86.7% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	753	641	562	1,281	1,207	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	45.1	47.0	81.4	45.4	33.5
	798	688	643	1,326	1,241
	315	272	224	599	657
	46.8	37.7	70.8	25.3	10.5
	−45.0	−26.9	−7.1	37.1	−12.3
	147	138	118	153	136
	0.3	1.4	2.9	51.1	92.2
	32.3	30.6	24.5	53.3	57.4
	186	176	176	212	187
	681	628	609	1,131	1,128
	104	45.1	−19.4	254	229
	71.3	14.5	−43.9	201	172
Profit
	116	60.1	34.6	195	113
	−11.8	−11.0	223	387	−26.6
	104	49.0	258	582	86.5
	26.4	13.1	3.3	162	15.3
	−8.3	−5.4	4.0	−10.8	23.4
	18.1	7.7	7.3	151	38.7
	−2.9	0.0	0.0	−9.0	0.0
	0.2	0.1	−0.1	0.0	−0.2
	83.6	41.4	250	421	47.6
	83.3	41.3	251	421	47.8
	2.1	−0.9	17.2	0.3	0.3
	85.6	40.5	268	422	47.9
	—	—	250	421	47.6
Per share
	₹9.76	₹4.95	₹37.25	₹71.24	₹8.06
	₹9.65	₹4.84	₹35.21	₹71.24	₹8.06
Other comprehensive income — detail
	2.1	−0.9	17.2	—	—
	0.9	0.9	0.0	—	—
	−3.0	0.0	−17.2	—	—
	—	—	—	−0.3	−0.3
	—	—	—	421	47.6
Per share — as-filed variants
	₹9.76	₹4.95	₹37.25	₹71.24	₹8.06
	₹9.65	₹4.84	₹35.21	₹71.24	₹8.06
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	436	359	274	619	552
	57.9%	56.0%	48.7%	48.4%	45.7%
Adjusted (ex-exceptional items) — derived
	116	60.1	34.6	195	113
	−11.8	−11.0	223	387	−26.6
	93.3	50.7	33.6	135	62.3
	₹10.90	₹6.06	₹4.99	₹22.88	₹10.55

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

INDSWFTLAB₹378.95

Ind-Swift Laboratories Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersSMSPHARMA SOLARA DCAL HIKAL UNICHEMLAB GUFICBIO PANACEABIO RPGLIFEMcap ₹3,291 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Revenue from Operations	1,207.3	1,280.9	561.7	641.3	752.6
Other Income	33.5	45.4	81.4	47.0	45.1
Total Income	1,240.8	1,326.3	643.1	688.3	797.6
Expenses
+ Cost of Materials Consumed	657.5	599.1	224.2	271.7	314.9
+ Purchases of Stock-in-Trade	10.5	25.3	70.8	37.7	46.8
+ Changes in Inventories	-12.3	37.1	-7.1	-26.9	-45.0
+ Employee Benefit Expense	135.8	152.8	117.5	138.0	146.7
+ Finance Costs	92.2	51.1	2.9	1.4	0.3
+ Depreciation & Amortisation	57.4	53.3	24.5	30.6	32.3
+ Other Expenses	186.7	212.4	175.6	175.8	185.6
Total Expenses	1,127.6	1,131.1	608.5	628.2	681.5
EBITDA	229.2	254.2	-19.4	45.1	103.6
EBIT	171.8	200.9	-43.9	14.5	71.3
Profit
PBT before Exceptional Items	113.2	195.2	34.6	60.1	116.1
+ Exceptional Items	-26.6	386.6	223.2	-11.0	-11.8
Pretax Income	86.5	581.8	257.8	49.0	104.3
+ Current Tax	15.3	162.1	3.3	13.1	26.4
+ Deferred Tax	23.4	-10.8	4.0	-5.4	-8.3
Tax Expense	38.7	151.3	7.3	7.7	18.1
+ Net Movement in Regulatory Deferral Balances	0.0	-9.0	0.0	0.0	-2.9
+ Share of Associates & JVs	-0.2	0.0	-0.1	0.1	0.2
Net Income	47.6	421.5	250.5	41.4	83.6
+ Net Income — Continuing Ops	47.8	421.5	250.5	41.3	83.3
+ Other Comprehensive Income	0.3	0.3	17.2	-0.9	2.1
Total Comprehensive Income	47.9	421.8	267.7	40.5	85.6
Net Income to Common	47.6	421.5	250.5	—	—
Per Share
Basic EPS	8.06	71.24	37.25	4.95	9.76
Diluted EPS	8.06	71.24	35.21	4.84	9.65
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	17.2	-0.9	2.1
+ Tax on Items NOT to be Reclassified	—	—	0.0	0.9	0.9
+ Tax on Items to be Reclassified	—	—	-17.2	0.0	-3.0
+ Tax on Items to be Reclassified — alt tag	-0.3	-0.3	—	—	—
Comprehensive Income — Owners of Parent	47.6	421.5	—	—	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	8.06	71.24	37.25	4.95	9.76
Diluted EPS — Continuing Operations	8.06	71.24	35.21	4.84	9.65
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	551.7	619.4	273.8	358.8	436.0
Gross Margin %	45.70	48.36	48.74	55.96	57.94
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	113.2	195.2	34.6	60.1	116.1
− Exceptional Items (reconciliation)	-26.6	386.6	223.2	-11.0	-11.8
Net Income Adj (tax-effected)	62.3	135.4	33.6	50.7	93.3
EPS Adj	10.55	22.88	4.99	6.06	10.90
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00
Filed Debt Equity	2.00	0.00	—	—	—
Filed Dscr	2.00	6.00	—	—	—
Filed Iscr	3.00	6.00	—	—	—
Paid Up Equity Capital	59.1	59.1	68.7	86.8	87.0

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.